PureTech Health PLC Sponsored ADR
PRTCY Healthcare Biotechnology
PureTech Health PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 3.50% from fiscal 2024.
Follow PRTCY
PureTech Health PLC Sponsored ADR (PRTCY) EV/Sales
As of 15 October 2026, PureTech Health PLC Sponsored ADR (PRTCY) trades at a EV/Sales of −9.1×. Over the past ten years it has ranged from −16.1× (December 2024) to −6.0× (December 2020); the current reading is higher than 98% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −9.1× | — |
| FY2024 | −12.1× | — |
| FY2023 | −10.4× | — |
| FY2022 | −10.3× | — |
| FY2022 | −16.0× | — |
| FY2021 | −16.0× | — |
| FY2021 | −11.0× | — |
| FY2020 | −11.0× | — |
| FY2020 | −6.0× | — |
| FY2019 | −6.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 265× | 0.33% |
| Dec 2022 | 264× | 34.59% |
| Jun 2022 | 196× | (43.73%) |
| Dec 2021 | 349× | (40.78%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR | −9.1× |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | 0.8× |
| PRTA Prothena Corporation plc compare | 2.7× |
| CAPR Capricor Therapeutics, Inc. compare | 7.4× |
| PROK ProKidney Corp. compare | 81.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)